Pyralvex Solution Oromucosal Solution
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT
Pyralvex solution, oromucosal solution
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
PYRALVEX contains the following active ingredients in each 1ml of solution:
Rhubarb extract 50 mg (equivalent to 5 mg anthraquinone glycosides)
Salicylic Acid 10 mg
3 PHARMACEUTICAL FORM
Oromucosal solution.
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
For the symptomatic relief of pain associated with recurrent mouth ulcers and denture irritation.
4.2 Posology and method of administration
Adults (including the elderly) and children 16 years and over: To be applied to the inflamed oral mucosa (after removing any dentures) three or four times daily using the brush provided.
Seek medical advice if no improvement in condition - maximum length of use is 7 days.
Children: Contraindicated below the age of 16 years.
4.3 Contraindications
Hypersensitivity to any of the constituents.
Not to be used in children and adolescents under the age of 16. This is because there is a possible association between salicylates and Reye’s Syndrome when given to children. Reye’s Syndrome is a very rare disease which affects the brain and liver and can be fatal.
4.4 Special warnings and precautions for use
Salicylate toxicity can result if the stated frequency of application is exceeded. Each bottle of PYRALVEX should be used by only one person.
Pyralvex contains 59,5 vol.-% alcohol.
4.5 Interaction with other medicinal products and other forms of interaction
None known.
4.6 Pregnancy and lactation
Animal studies are insufficient with respect to effects on pregnancy and-or embryonal/foetal development. The potential risk for humans is unknown. Caution should be exercised when prescribing to pregnant women.
Anthranoid glycosides derived from rhubarb may be excreted in breast milk. However, at therapeutic doses of PYRALVEX, it is not known whether these, or salicylic acid are excreted in breast milk. A decision on whether to continue breastfeeding or to continue therapy with PYRALVEX should be made taking into account the benefit of breast-feeding to the child and benefit of PYRALVEX therapy to the woman.
4.7 Effects on ability to drive and use machines
None.
4.8 Undesirable effects
Within the system organ classes, adverse reactions are listed under headings of frequency
(number of patients expected to experience the reaction), using the following categories:
Very common (>1/10)
Common (>1/100 to <1/10)
Uncommon (>1/1,000 to <1/100)
Rare (>1/10,000 to <1/1,000)
Very rare (<1/10,000)
Not known (cannot be estimated from the available data)
Immune system disorders
Very rare: Allergic reactions
Gastrointestinal disorders
Common: Temporary discolouration of teeth or oral mucosa.
Skin and subcutaneous tissue disorders
Frequency not known: Rash and urticaria
General disorders and administration site conditions
Very common: Transient local burning sensation at the site of application.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
4.9 Overdose
Overdose associated with local application is unlikely, although the extent of systemic absorption of salicylic acid and anthranoid derivatives is not known. Systemic overdose following ingestion might lead to abdominal cramping, diarrhoea and possibly salicylism (presenting as hyperventilation, tinnitus, deafness, vasodilation, sweating).
Salicylate toxicity can result if stated frequency of application is exceeded. Do not exceed the stated frequency of application.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacological studies have shown that the active ingredients of PYRALVEX display anti-inflammatory, analgesic and anti-microbial properties, which are the basis of its clinical efficacy.
5.2 Pharmacokinetic properties
Systemic availability of PYRALVEX is unlikely to be significant, owing to the low levels of ingredients administered.
5.3 Preclinical safety data
There is some evidence of genotoxic risk with rhubarb extract and related anthranoids, the relevance of these findings to PYRALVEX is unknown.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Ethanol
Water
6.2 Incompatibilities
None known.
6.3 Shelf life
The shelf life is 3 years.
6.4 Special precautions for storage
Store below 25°C.
6.5 Nature and contents of container
An amber glass bottle with brush applicator containing 10ml of solution.
6.6 Special precautions for disposal
Avoid rinsing of the mouth or eating for 15 minutes after application. Any discolouration which may occur will disappear during normal cleaning of the teeth.
7 MARKETING AUTHORISATION HOLDER
Meda Pharmaceuticals Ltd Skyway House Parsonage Road Takeley
Bishop’s Stortford CM22 6PU
8 MARKETING AUTHORISATION NUMBER(S)
PL 15142/0244
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
18/06/2011
10 DATE OF REVISION OF THE TEXT
26/02/2014